Remlarsen    Actively Recruiting in the United States

➤ A Phase 2 clinical trial, MRG201-30-201, designed to investigate the efficacy, safety and tolerability of intradermal administration of remlarsen (MRG-201) in subjects with a history of keloids.

MRG-201 is a replacement for microRNA-29, which has been found at abnormally low levels in a number of pathological fibrotic conditions, including cutaneous, cardiac, renal, hepatic, pulmonary and ocular fibrosis, as well as systemic sclerosis.

More information on this study can be found here.

More information about remlarsen can be found here.